Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in pre-clinical models of aggressive lymphomas

NIAID Data Ecosystem2026-03-10 收录

淋巴瘤药物联合疗法

临床前药效机制

数据链接：

https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE76757 数据链接链接失效反馈

官方服务：

资源简介：

assess the efficacy of Pimasertib to characterize its mechanism of action GEP analysis of one lymphoma cell line with and without treatment with Pimasertib

创建时间：

2018-08-13

Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in pre-clinical models of aggressive lymphomas

资源简介：

相关数据集